52-week Open Label Safety-Tolerability Study
ConditionSchizophrenia
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorLB Pharmaceuticals Inc.
About this trial
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
Eligibility criteria
Qualifiers
Provide ICF
Patients clinically stable PANSS </= 70 at screening
CGI-S </+ 3 at screening
Medically stable
Disqualifiers
Sexually active M/F patients not willing to use highly effective contraception
Breast feeding
History of treatment resistance to schizophrenia medications
DSM-5 current diagnosis other than schizophrenia
Trial design
Treatments tested in this trial
- LB-102
Treatment groups
900 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov